COMPANY RESEARCHHSK47388 is an oral IL-23 inhibitory peptide in Phase 2 for psoriasis. Relative exposure data support its enhancer formulation, while cyclization and absolute oral bioavailability remain unconfirmed.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Disease tags match recorded text mentions and require program-level verification.
Phase 1 human data and formulation-enhanced PK have been disclosed for HSK47388. A psoriasis Phase 2 registry entry was located, but its dynamic text was not extracted, so Phase 2 is not yet verified.
The January 2026 company release states that psoriasis Phase 2 began in Q4 2025; cyclization is not fully disclosed.
Original Haisco disclosures identify HSK29116 as an oral BTK PROTAC; the NCI Drug Dictionary specifies CRBN recruitment.
HSK40118 previously received clinical authorization, but its continued active advancement cannot be inferred automatically from the latest annual report.
| Program / service | Target / indication | Representative stage | Evidence & scope |
|---|---|---|---|
| HSK47388 | IL-23 pathway · Psoriasis / ulcerative colitis | Phase 2 | Company-disclosed Phase 1 and enhanced-formulation PK; no absolute bioavailability |
| HSK29116 | BTK · See individual trial / indication; not individually confirmed in this review | Phase 1 | IND / clinical entry disclosed; public human results not confirmed in this review |
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
No cataloged update explicitly mentions this company.
Amphista announced an ASH oral presentation on AMX-883-mediated BRD9 degradation, describing disruption of hematopoietic transcriptional programs, myeloid differentiation, and reduced leukemic stem-cell frequency in experimental work. A separate abstract outlines the ongoing Phase 1 BRAMLIE study in AML and high-risk myelodysplastic syndrome. The announcement does not establish clinical efficacy for AMX-883.
Nurix announced updated Phase 1a/1b findings for its oral BTK degrader bexobrutideg (NX-5948) in relapsed or refractory CLL/SLL. The ASH presentation will include patients previously exposed to covalent BTK inhibitors and data at the recommended Phase 2 dose of 600 mg once daily. The release describes durable activity without providing numerical response rates.
A PNAS study reports RHV, a tetravalent bispecific protein designed to internalize and lysosomally degrade VCAM-1 and VEGFR on pathological vessels. The original abstract describes activity in mouse choroidal neovascularization models, including efficacy comparable to aflibercept at one-quarter of the molar dose. This is preclinical extracellular receptor degradation, distinct from an intracellular small-molecule PROTAC.
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinInclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.
